Sign In
Buy BAYRY
$13.89
-0.110 (-0.786%)
At Close: Jul 31, 2026
Bayer and Kumquat Biosciences Enter Global Exclusive License and Collaboration in Precision Oncology
08:00am, Tuesday, 12'th Aug 2025
BERLIN & SAN DIEGO--(BUSINESS WIRE)--Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced that they have entered into an exclus
Bayer adds cancer drug candidate to portfolio with $1.3-billion Kumquat deal
03:42am, Tuesday, 12'th Aug 2025
German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.
Bayer, Kumquat Biosciences Team Up on New Potential Cancer Drug
03:11am, Tuesday, 12'th Aug 2025
Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will take the drug to market.
Bayer A.G. (BAYZF) Q2 2025 Earnings Call Transcript
10:34pm, Wednesday, 06'th Aug 2025
Bayer A.G. (OTCPK:BAYZF) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Jost Reinhard - Senior VP & Head of Investor Relations Rodrigo Santos - Member of Management Bo
Bayer Beats on Q2 Earnings and Sales, Raises '25 Adjusted Sales View
11:36am, Wednesday, 06'th Aug 2025
BAYRY beats on Q2 earnings and raises 2025 sales outlook (on a currency-adjusted basis) as pharma growth offsets currency and Xarelto headwinds.
Bayer says it has cut 12,000 jobs so far under restructuring push
01:53am, Wednesday, 06'th Aug 2025
Bayer said on Wednesday it had cut about 12,000 full-time positions since the start of a restructuring programme to speed up decision-making and reduce managerial and administrative positions.
Bayer Stock Is Soaring Ahead Of Its Earnings Release
09:40am, Tuesday, 05'th Aug 2025
Bayer Aktiengesellschaft raised its 2025 sales and earnings guidance, reflecting improved performance in its pharmaceuticals division and better-than-expected results. Litigation risks have eased sign
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
Bayer increases Roundup litigation provisions by $1.37 billion
05:45pm, Thursday, 31'st Jul 2025
German pharmaceutical company Bayer said on Thursday it had set aside an additional 1.2 billion euros ($1.37 billion) in provisions to address ongoing Roundup litigation in the United States.
French court finds complaint brought by family in Bayer glyphosate case inadmissible, media says
06:36am, Thursday, 31'st Jul 2025
A French court ruled on Thursday that a complaint brought by a family against Bayer claiming their son's disabilities were the result of his mother's exposure to glyphosate when pregnant was inadmissi
US FDA extends review of Bayer's menopause relief drug
01:00pm, Friday, 25'th Jul 2025
The U.S. Food and Drug Administration has extended its review of Bayer's experimental menopause relief drug, the German drugmaker said on Friday.
Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause
12:30pm, Friday, 25'th Jul 2025
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause.
Best Value Stocks to Buy for July 22nd
10:01am, Tuesday, 22'nd Jul 2025
OPRT, BAYRY and SHG made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 22, 2025.
New Strong Buy Stocks for July 22nd
07:10am, Tuesday, 22'nd Jul 2025
BTG, PGR, BAYRY, BCH and LNW have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2025.
